Ruti Aga: How a Forged Prescription Turned a Two-Year Case Into Six

The first roar in Bhubaneswar came in a half-empty stadium in 2026. Asian Athletics Championships. Neeraj Chopra's 85.23m, and then an interview with a quiet young man who refused to wear his own achievement like armour. I was hosting Star Sports' live coverage that evening, and I pitched 'The Track Diaries' on the strength of that belief — that the real story of any sport sits above its numbers.

Eight years later there is another piece of paper on my desk, and it is also the story of a sport — except this time it is not a number, it is a document. Ruti Aga, the Ethiopian marathoner, has been banned for six years by the Athletics Integrity Unit. One finding was a prohibited substance. The heavier finding was a forged prescription, which the AIU says was produced by a member of her own family. The athlete who won the 2026 Tokyo Marathon is now writing the end of her career not with a two-year drug sanction but with a four-year paperwork sanction.

Context: what the statement says, and what it does not

The AIU's Thursday statement records that Aga's sample was collected after a half marathon in China in March — a race she won. She has been provisionally suspended since 10 September, and that same date has now been fixed as the start of the six-year ban. At 32, the arithmetic is blunt: she will be near 38 when it ends, entirely outside the 2028 Olympic cycle.

The sanction arithmetic is where the case actually speaks. Two years for presence, four for tampering, six in total. In the Code's language, two years means the panel accepted the substance was in her body without proven intent to cheat; four years means it treated the fabrication of documents as fully culpable conduct. Backdating to 10 September is no concession — provisional suspension time counts against the ban, and the athlete gains nothing in real terms. Every host knows the moment before the lights, when the arena is still a rumour; every case has the same moment, when the verdict is still only a file.

There is no performance content here at all. Her time in that Chinese half marathon, the strength of the field, any official mark — none of it is public. The scoreboard is blank, and a blank scoreboard demands restraint. Inferring form from the word 'won' is like forecasting weather from crowd noise. I have watched crowds become weather — impossible to predict, impossible to ignore.

What survives is the record: the 2026 Tokyo title, and three second-place finishes at World Marathon Majors. That is a genuinely elite marathoner's CV. And because the case is anchored to a March race in a later year, results up to 2026 are not automatically annulled — not without a formal finding. The source does not state the disqualification scope.

Core: the wrong drug was never the point — the wrong method was

A technical correction matters here, because the entire case hinges on it. Most reporting has called methylprednisolone a 'prohibited steroid'. It is not an anabolic steroid. It is a glucocorticoid — WADA List class S9 — and under the current List, glucocorticoids are prohibited in-competition only, and only via injection, oral or rectal routes. A therapeutic knee injection out of competition is entirely legal medicine.

Which means the case was never about steroid use. It was about route and timing. A road race's testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. Aga had a legitimate defence available: medical records, a timing explanation, a documented injury history. On that path the sanction could have been far lighter, and conceivably zero.

And that is the real story: what killed the defence was not the substance, it was the defence being fake. According to the AIU, Aga cited a knee injury. The 'doctor' who wrote the prescription was a family member with no medical registration. The clinic whose stamp appeared on it did not exist. Asked to explain, that person claimed an 'old prescription pad from a former workplace' — a claim the clinic explicitly disowned.

Three independent verification points, three failures. This is not a clerical slip; it is the signature of a system in which an elite athlete operates without a credentialed team physician. An athlete with a functioning TUE process and real records does not commission a forged prescription. A forged prescription is what you commission when you have nothing real to submit.

There is a further layer that turns this from an individual story into a structural one. Knee pathology is the most familiar load-bearing failure among marathoners, and a glucocorticoid injection is the cheapest, most available tool for masking knee pain. Informal medical networks grow precisely around that need in the high-altitude Ethiopian-Kenyan training clusters. China's label races — large appearance fees, deep East African elite fields — are that network's most lucrative income tier, and now the AIU's highest-yield testing ground as well. The appearance-fee economy and the testing economy are colliding in the same races, and a single runner is paying the bill.

Contrarian: not a triumph of rigour — a triumph of document verification

By any measure, this outcome is not a win for clean sport as usually claimed. It is a win for paperwork verification. Glucocorticoids confer no proven endurance benefit. The six-year ban is not 'proportionate' because the substance helped her, but because the athlete built her own defence. The four years are for concealing, not for dosing. That is the hardest truth in the file, and the easiest one to skip past.

Then there is the blind spot. The AIU named only the family member. No agent, manager or training camp is mentioned as investigated. Prescriptions like this are not forged alone; someone advises, someone approves, someone demands paper for a file. Until that link is examined, the sanction keeps landing on the person rather than the system — and on a person who was already carrying an injured knee.

Second, the near-universal media framing of this as a 'steroid case'. That framing shapes public judgment. A report written on the wrong pharmacological classification makes fair comparison impossible — neither the athlete nor the regulator can be understood properly through it.

Third, the numbers. Ethiopia's women's marathon depth is so extreme that removing a 2:18–2:20 performer is invisible in national-team calculus. This case is therefore about governance, not competition. The real question is why an athlete of that level had no infrastructure for documenting a knee injection.

Takeaway

The enforcement frontier has shifted from detection to document verification. An appeal window stays open, but a forged-document finding does not bend to interpretation. A return at 38 is effectively closed by Ethiopian selection depth. The question is not whether she races again — it is where the next runner with a swollen knee is supposed to get a real prescription.